{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:03:12Z","timestamp":1787241792636,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.dsx.2020.11.015","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T19:17:57Z","timestamp":1605813477000},"page":"2233-2239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-6137","authenticated-orcid":false,"given":"Mohammad Shafi","family":"Kuchay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-0036","authenticated-orcid":false,"given":"Narendra Singh","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dsx.2020.11.015_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2012-3093","article-title":"Clinical Review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.015_bib2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.14327","article-title":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 national health and nutrition examination survey","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.015_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/qjmed\/hct198","article-title":"Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management","volume":"107","author":"Armstrong","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.dsx.2020.11.015_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.11.015_bib5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.dsx.2020.11.015_bib6","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.dsx.2020.11.015_bib7","first-page":"S1665","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.dsx.2020.11.015_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.015_bib9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.dsx.2020.11.015_bib10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of Fib-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.015_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.dsx.2020.11.015_bib12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/2050640619865133","article-title":"Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease","volume":"7","author":"Staufer","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"5","key":"10.1016\/j.dsx.2020.11.015_bib13","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.11.015_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.11.015_bib15","first-page":"53","article-title":"Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis","volume":"19","author":"Lupsor","year":"2010","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.dsx.2020.11.015_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.dsx.2020.11.015_bib17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2020.11.015_bib18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2020.11.015_bib19","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.11.015_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.dsx.2020.11.015_bib21","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.015_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147237","article-title":"Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score","volume":"11","author":"Tapper","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.dsx.2020.11.015_bib23","article-title":"Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease","author":"Shima","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"issue":"8","key":"10.1016\/j.dsx.2020.11.015_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202393","article-title":"Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease","volume":"13","author":"Peleg","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.dsx.2020.11.015_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jceh.2019.02.005","article-title":"Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how?","volume":"9","author":"Choudhary","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.dsx.2020.11.015_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.arcmed.2009.07.009","article-title":"High prevalence of coronary heart disease in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"40","author":"Lu","year":"2009","journal-title":"Arch Med Res"},{"key":"10.1016\/j.dsx.2020.11.015_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1464-5491.2006.01817.x","article-title":"Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease","volume":"23","author":"Targher","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2020.11.015_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2020.11.015_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.015_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cld.726","article-title":"Spotlight on impactful research: increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systemic review and meta-analysis","volume":"12","author":"von Roenn","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dsx.2020.11.015_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"Singal","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.dsx.2020.11.015_bib32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","article-title":"Liver transplantation for nonalcoholic steatohepatitis: the new epidemic","volume":"256","author":"Agopian","year":"2012","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.015_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jceh.2015.02.006","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian national association for the study of the liver, endocrine society of India, Indian college of cardiology and Indian society of gastroenterology","volume":"5","author":"Duseja","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.dsx.2020.11.015_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.11.015_bib35","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2020.11.015_bib36","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2020.11.015_bib37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2020.11.015_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.015_bib39","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.015_bib40","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.015_bib41","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2020.11.015_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.11.015_bib43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dsx.2020.11.015_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.015_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dsx.2020.11.015_bib46","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2020.11.015_bib47","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"}],"updated-by":[{"DOI":"10.1016\/j.dsx.2022.102504","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212030480X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212030480X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:13:17Z","timestamp":1761729197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187140212030480X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S187140212030480X"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.11.015","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}